Literature DB >> 15831824

Clostridium difficile toxins: mechanism of action and role in disease.

Daniel E Voth1, Jimmy D Ballard.   

Abstract

As the leading cause of hospital-acquired diarrhea, Clostridium difficile colonizes the large bowel of patients undergoing antibiotic therapy and produces two toxins, which cause notable disease pathologies. These two toxins, TcdA and TcdB, are encoded on a pathogenicity locus along with negative and positive regulators of their expression. Following expression and release from the bacterium, TcdA and TcdB translocate to the cytosol of target cells and inactivate small GTP-binding proteins, which include Rho, Rac, and Cdc42. Inactivation of these substrates occurs through monoglucosylation of a single reactive threonine, which lies within the effector-binding loop and coordinates a divalent cation critical to binding GTP. By glucosylating small GTPases, TcdA and TcdB cause actin condensation and cell rounding, which is followed by death of the cell. TcdA elicits effects primarily within the intestinal epithelium, while TcdB has a broader cell tropism. Important advances in the study of these toxins have been made in the past 15 years, and these are detailed in this review. The domains, subdomains, and residues of these toxins important for receptor binding and enzymatic activity have been elegantly studied and are highlighted herein. Furthermore, there have been major advances in defining the role of these toxins in modulating the inflammatory events involving the disruption of cell junctions, neuronal activation, cytokine production, and infiltration by polymorphonuclear cells. Collectively, the present review provides a comprehensive update on TcdA and TcdB's mechanism of action as well as the role of these toxins in disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831824      PMCID: PMC1082799          DOI: 10.1128/CMR.18.2.247-263.2005

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  187 in total

1.  Virulence of Clostridium difficile toxin A negative strains.

Authors:  M H Wilcox; W N Fawley
Journal:  J Hosp Infect       Date:  2001-05       Impact factor: 3.926

2.  Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A.

Authors:  K S Kirkwood; N W Bunnett; J Maa; I Castagliolo; B Liu; N Gerard; J Zacks; C Pothoulakis; E F Grady
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-08       Impact factor: 4.052

3.  Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile.

Authors:  Kai Soo Tan; Boon Yu Wee; Keang Peng Song
Journal:  J Med Microbiol       Date:  2001-07       Impact factor: 2.472

4.  Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor.

Authors:  N Mani; B Dupuy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

5.  Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

Authors:  K L Kotloff; S S Wasserman; G A Losonsky; W Thomas; R Nichols; R Edelman; M Bridwell; T P Monath
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Low pH-induced formation of ion channels by clostridium difficile toxin B in target cells.

Authors:  H Barth; G Pfeifer; F Hofmann; E Maier; R Benz; K Aktories
Journal:  J Biol Chem       Date:  2001-01-04       Impact factor: 5.157

7.  Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes.

Authors:  Maja Rupnik; Jon S Brazier; Brian I Duerden; Miklavz Grabnar; Simon L J Stubbs
Journal:  Microbiology (Reading)       Date:  2001-02       Impact factor: 2.777

8.  Infection of hamsters with epidemiologically important strains of Clostridium difficile.

Authors:  S P Sambol; J K Tang; M M Merrigan; S Johnson; D N Gerding
Journal:  J Infect Dis       Date:  2001-05-11       Impact factor: 5.226

9.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

10.  Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins.

Authors:  A Nusrat; C von Eichel-Streiber; J R Turner; P Verkade; J L Madara; C A Parkos
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

View more
  412 in total

1.  Molecular characteristics of Clostridium perfringens TpeL toxin and consequences of mono-O-GlcNAcylation of Ras in living cells.

Authors:  Gregor Guttenberg; Sven Hornei; Thomas Jank; Carsten Schwan; Wei Lü; Oliver Einsle; Panagiotis Papatheodorou; Klaus Aktories
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

2.  Quantitative proteomic analysis of type III secretome of enteropathogenic Escherichia coli reveals an expanded effector repertoire for attaching/effacing bacterial pathogens.

Authors:  Wanyin Deng; Hong B Yu; Carmen L de Hoog; Nikolay Stoynov; Yuling Li; Leonard J Foster; B Brett Finlay
Journal:  Mol Cell Proteomics       Date:  2012-06-01       Impact factor: 5.911

Review 3.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

Review 4.  Allosteric regulation of protease activity by small molecules.

Authors:  Aimee Shen
Journal:  Mol Biosyst       Date:  2010-06-10

5.  Transcriptional profiling of Clostridium difficile and Caco-2 cells during infection.

Authors:  Tavan Janvilisri; Joy Scaria; Yung-Fu Chang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

6.  Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury.

Authors:  Simon A Hirota; Kyla Fines; Jeffrey Ng; Danya Traboulsi; Josh Lee; Eikichi Ihara; Yan Li; William G Willmore; Daniel Chung; Melanie M Scully; Thomas Louie; Shaun Medlicott; Manigandan Lejeune; Kris Chadee; Glen Armstrong; Sean P Colgan; Daniel A Muruve; Justin A MacDonald; Paul L Beck
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

7.  Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A.

Authors:  Isa Kreimeyer; Friederike Euler; Alexander Marckscheffel; Helma Tatge; Andreas Pich; Alexandra Olling; Janett Schwarz; Ingo Just; Ralf Gerhard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-11-03       Impact factor: 3.000

8.  Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.

Authors:  Jinfu Xie; Julie Zorman; Lani Indrawati; Melanie Horton; Keri Soring; Joseph M Antonello; Yuhua Zhang; Susan Secore; Matthew Miezeiewski; Su Wang; Anthony D Kanavage; Julie M Skinner; Irene Rogers; Jean-Luc Bodmer; Jon H Heinrichs
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

9.  Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis.

Authors:  Graeme S Cottrell; Silvia Amadesi; Stella Pikios; Eric Camerer; J Adam Willardsen; Brett R Murphy; George H Caughey; Paul J Wolters; Shaun R Coughlin; Anders Peterson; Wolfgang Knecht; Charalabos Pothoulakis; Nigel W Bunnett; Eileen F Grady
Journal:  Gastroenterology       Date:  2007-04-13       Impact factor: 22.682

10.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.